TY - JOUR
T1 - High-dose cytosine arabinoside in multiple myeloma
AU - Kantarjian, Hagop
AU - Dreicer, Robert
AU - Barlogie, Barthel
AU - Plunkett, William
AU - Alexanian, Raymond
PY - 1984/2
Y1 - 1984/2
N2 - In 14 patients with advanced refractory multiple myeloma, the effect of high-dose cytosine arabinoside (ara-C) administration was evaluated. There was one partial remission among 13 evaluable patients who received 2 g/m2 intravenously over 2 hr every 12 hr, for a total of 2-8 g/m2 per course, repeated every 3-4 weeks. Myelosuppression constituted the dose-limiting toxicity, causing two treatment-related deaths from infection and bleeding. Prior extensive therapy, a low percentage of cells in S phase and low levels of intracellular ara-CTP accumulation in the bone marrow could explain the resistance of myeloma to this treatment.
AB - In 14 patients with advanced refractory multiple myeloma, the effect of high-dose cytosine arabinoside (ara-C) administration was evaluated. There was one partial remission among 13 evaluable patients who received 2 g/m2 intravenously over 2 hr every 12 hr, for a total of 2-8 g/m2 per course, repeated every 3-4 weeks. Myelosuppression constituted the dose-limiting toxicity, causing two treatment-related deaths from infection and bleeding. Prior extensive therapy, a low percentage of cells in S phase and low levels of intracellular ara-CTP accumulation in the bone marrow could explain the resistance of myeloma to this treatment.
UR - http://www.scopus.com/inward/record.url?scp=0021351123&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021351123&partnerID=8YFLogxK
U2 - 10.1016/0277-5379(84)90188-3
DO - 10.1016/0277-5379(84)90188-3
M3 - Article
C2 - 6538488
AN - SCOPUS:0021351123
SN - 0277-5379
VL - 20
SP - 227
EP - 231
JO - European Journal of Cancer and Clinical Oncology
JF - European Journal of Cancer and Clinical Oncology
IS - 2
ER -